Humacyte (NASDAQ:HUMA) Stock Price Down 6.7% - Time to Sell?

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) traded down 6.7% during mid-day trading on Tuesday . The stock traded as low as $4.04 and last traded at $4.05. 545,669 shares changed hands during trading, a decline of 77% from the average session volume of 2,407,047 shares. The stock had previously closed at $4.34.

Analyst Ratings Changes

Several analysts recently weighed in on HUMA shares. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a "neutral" rating in a research note on Friday, October 18th. TD Cowen reiterated a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Thursday, November 21st. Finally, Benchmark restated a "buy" rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Humacyte currently has a consensus rating of "Buy" and an average target price of $13.00.

Humacyte Stock Down 12.6 %

The firm has a market cap of $477.63 million, a price-to-earnings ratio of -2.83 and a beta of 1.38. The firm has a 50 day moving average of $4.96 and a 200 day moving average of $5.93. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insiders Place Their Bets

In related news, CEO Laura E. Niklason sold 261,369 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares of the company's stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Corporate insiders own 11.20% of the company's stock.

Institutional Trading of Humacyte

Several hedge funds have recently bought and sold shares of the business. Endowment Wealth Management Inc. raised its stake in shares of Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company's stock worth $482,000 after purchasing an additional 3,000 shares during the last quarter. nVerses Capital LLC bought a new stake in Humacyte during the second quarter worth $28,000. Private Advisor Group LLC grew its holdings in Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company's stock worth $2,030,000 after buying an additional 6,510 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company's stock valued at $168,000 after buying an additional 8,557 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company's stock valued at $125,000 after acquiring an additional 8,965 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.